39.11 0.00 (0.00%)
After hours: 4:02PM EDT
|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||38.97 - 39.22|
|52 Week Range||33.03 - 40.43|
|PE Ratio (TTM)||22.30|
|Forward Dividend & Yield||0.70 (1.83%)|
|1y Target Est||42.90|
Smith & Nephew plc (LSE:SN.) trades with a trailing P/E of 21.7x, which is lower than the industry average of 29.6x. While this makes SN. appear like a great stockRead More...
Smith & Nephew plc (LSE:SN.) delivered an ROE of 16.52% over the past 12 months, which is an impressive feat relative to its industry average of 10.23% during the sameRead More...
A little known private-equity executive will steer WPP PLC through one of its stormiest periods following the resignation last weekend of Martin Sorrell.
One of Massachusetts’ largest medical device employers, London-based Smith & Nephew, has named a new CEO who’ll be familiar to that company’s 1,100 Massachusetts employees.
Artificial hip and knee maker Smith & Nephew (SN.L), a perennial target of takeover speculation, said on Wednesday it had appointed a new chief executive with a track record of deal-making. Namal Nawana, who will replace Olivier Bohuon as CEO of the British company next month, most recently headed medical diagnostics firm Alere, where he oversaw its $5.3 billion sale to Abbott (ABT.N) in 2017. The medical technology firm, which also has wound-care and sports medicine units, is under pressure to improve margins and find new sources of growth as it competes with bigger rivals.
Smith & Nephew plc (SNN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
Medical equipment supplier Smith & Nephew Inc. has selected its Fort Worth facility to locate a $29 million project, creating 100 new jobs. Fort Worth beat out at least three other cities for the project.
LSE:SN), the global medical technology business, today announces the donation of more than $3M of trauma plates and screws, external fixation implants and instruments to The Podiatry Institute (PI). This equipment will be used to support ongoing educational courses conducted at the PI through the American Academy of Foot and Ankle Osteosynthesis (AAFAO). Smith & Nephew has been the sole sponsor of the comprehensive and advanced educational courses conducted by the PI and AAFAO for the past four years, contributing to resident education for nearly 1600 participants.
Measuring Smith & Nephew plc’s (LSE:SN.) track record of past performance is an insightful exercise for investors. It enables us to reflect on whether the company has met or exceedRead More...
VANCOUVER , March 7, 2018 /CNW/ - Trading resumes in: Company: Sunniva Inc. CSE Symbol: SNN Resumption (ET): 9:30 AM IIROC can make a decision to impose a temporary suspension (halt) of trading in a security ...
VANCOUVER , March 6, 2018 /CNW/ - The following issues have been halted by IIROC: Company: Sunniva Inc. CSE Symbol: SNN Reason: At the request of the Company Pending News Halt Time (ET): 3:43 PM IIROC ...
LONDON , March 6, 2018 /PRNewswire/ -- Smith & Nephew (NYSE:SNN, LSE: SN), the global medical technology business, is pleased to announce the launch of Q-FIX ™ CURVED, Q-FIX MINI and SUTUREFIX CURVED ...
LONDON , March 6, 2018 /PRNewswire/ -- Smith & Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the full commercial release of bi-cruciate retaining JOURNEY II XR total ...
Acclarent received FDA approval for its Acclarent Aera Balloon Dilation System for the treatment of ETD (eustachian tube dysfunction) in September 2016. For details, read Inside Johnson & Johnson’s Latest US Medical Device Launch. On February 27, 2018, Johnson & Johnson’s subsidiary Acclarent announced that the company received FDA approval for the expanded indication for Acclarent Aera.
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific
Smith & Nephew plc , the global medical technology business, today announces the publication of a randomised controlled trial demonstrating that the addition of ALLEVYN LIFE, Smith & Nephew’s leading multi-layer silicone adhesive foam dressing, to a standard care protocol significantly reduces the onset of pressure ulcers by 71% in elderly patients admitted to hospital for hip fracture1.
Dividends play a key role in compounding returns over time and can form a large part of our portfolio return. In the past 10 years Smith & Nephew plc (LSE:SN.)Read More...
LONDON , Jan. 18, 2018 /PRNewswire/ -- Smith & Nephew (NYSE: SNN; LSE: SN), the global medical technology business, today announces results showing a near 75% decrease in readmission rates for joint arthroplasties ...
Investors seeking to preserve capital in a volatile environment might consider large-cap stocks such as Smith & Nephew plc (LSE:SN.) a safer option. Risk-averse investors who are attracted to diversifiedRead More...
Smith & Nephew plc (LSE:SN.) is trading with a trailing P/E of 17.5x, which is lower than the industry average of 31.3x. While this makes SN. appear like a greatRead More...